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MaOBJECTIVES This study investigated the efﬁcacy and safety of novel oral anticoagulants (NOACs) in patients with atrial
ﬁbrillation (AF) and heart failure (HF) by a meta-analysis.
BACKGROUND AF is quite prevalent in patients with HF.
METHODS Four phase III clinical trials comparing NOACs to warfarin in patients with AF were included. Each patient was
deﬁned as affected by HF according to the criteria of the trial in which the patient was enrolled. Pre-speciﬁed outcomes
were the composite of stroke/systemic embolism (SSE); major, intracranial, and any bleeding; and cardiovascular (CV) and
all-cause death.
RESULTS A total of 55,011 patients were enrolled, 26,384 (48%) with HF, and 28,627 (52%) without HF; 27,518
receiving NOACs and 27,493 receiving warfarin (median, 70 years of age; 36% females; follow-up: 1.5 to 2.8 years). Rates
of SSE (relative risk [RR]: 0.98; 95% conﬁdence interval [CI]: 0.90 to 1.07]; p ¼ 0.68) and major bleeding (RR: 0.95;
95% CI: 0.88 to 1.03; p ¼ 0.21) were comparable in patients with and without HF. HF patients had reduced rates of any
(RR: 0.86; 95% CI: 0.81 to 0.91; p < 0.01) and intracranial (RR: 0.74 95% CI: 0.63 to 0.88; p < 0.01) bleeding but
increased rates of all-cause (RR: 1.70 95% CI: 1.31 to 2.19; p < 0.01) and CV death (RR: 2.05 95% CI: 1.66 to 2.55;
p < 0.01). NOACs, compared with warfarin signiﬁcantly reduced SSE and major, intracranial, and any bleeding, regardless
of the presence or absence of HF (pinteraction > 0.05 for each).
CONCLUSIONS Patients with AF and HF had increased mortality but reduced rates of intracranial and any bleeding
compared with the no-HF patients, with no differences in rates of SSE and major bleeding. NOACs signiﬁcantly reduced
SSE, major bleeding, and intracranial hemorrhage in HF patients. No interactions in efﬁcacy and safety of NOACs were
observed between AF patients with and without HF. (J Am Coll Cardiol HF 2016;4:870–80) © 2016 by the American
College of Cardiology Foundation.A trial ﬁbrillation (AF) is highly prevalent(up to 41%) in patients with heart failure(HF) (1), and the combination of HF and AF
is steadily increasing (2).
HF is considered a major risk factor for thrombo-
embolic (3,4) and bleeding risk (5,6) in patients with
AF and is included in the CHA2DS2-VASc score (7). In
addition, HF is widely recognized as a risk factor for
reduced time in therapeutic range (TTR) in AFehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Pﬁzer, and P
mmittee of trials sponsored by Bayer, Novartis, and Vifor. Dr. Lund has re
vartis, Bayer, ViforPharma, and HeartWare; and research grants to his
traZeneca. All other authors have reported that they have no relationship
nuscript received March 21, 2016; revised manuscript received June 3, 20patients taking warfarin-based anticoagulation ther-
apy (8,9), which may contribute to excess thrombo-
embolic and bleeding risk in AF patients with HF.
Novel oral anticoagulants (NOACs), due to their
more predictable therapeutic effect and more favor-
able hemorrhagic risk proﬁle, represent a particularly
attractive therapeutic option in AF patients with
concomitant HF. However, currently, no randomized
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ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
CI = conﬁdence interval
CV = cardiovascular
HF = heart failure
NOACs = novel oral
anticoagulants
NYHA = New York Heart
Association
RR = relative risk
SSE = stroke and systemic
embolism
TTR = time in therapeutic
range
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conducted, and only subgroup analyses from
the 4 major NOAC phase III clinical trials
reporting data for HF patients that have not
enough statistical power to investigate less
frequent events (i.e., intracranial bleeding)
are available (10–13). Notably, Ruff et al. (14),
in a recent meta-analysis, evaluated the
relative efﬁcacy and safety of NOACs across
clinically relevant patient subgroups, but no
data for patients with AF and concomitant
HF were reported. Xiong et al. (15) reported
in another meta-analysis a signiﬁcant
reduction of thromboembolic events and
major bleeding with high-dose NOACs
compared with warfarin in HF patients.SEE PAGE 881There was a similar incidence of both major bleeding
and thromboembolic events in AF patients with and
without HF treated with NOACs, but in this study,
data from the ENGAGE AF-TIMI 48 (Effective Anti-
coagulation with Factor Xa Next Generation in Atrial
Fibrillation–Thrombolysis In Myocardial Infarction
48) trial (13) were not available for most of the out-
comes and subanalyses.
Thus, the aim of the present analysis was to assess
the efﬁcacy and safety of NOACs in patients with AF
and HF enrolled in all phase III NOACs clinical trials
and to detect whether the efﬁcacy and safety of
NOACs differed between AF patients with and
without HF.
METHODS
STUDY SELECTION. The current analysis included
the 4 major phase III randomized clinical trials
comparing NOACs to warfarin in patients with AF:
ARISTOTLE (Apixaban for Reduction in Stroke and
Other Thromboembolic Events in Atrial Fibrillation)
trial, comparing apixaban, a direct factor Xa inhibi-
tor, with warfarin (10); the RE-LY (Randomized
Evaluation of Long Term Anticoagulation Therapy)
trial, comparing dabigatran, a direct inhibitor of
thrombin, with warfarin (11); the ROCKET AF (Rivar-
oxaban Once Daily Oral Direct Factor Xa Inhibition
Compared with Vitamin K Antagonism for Prevention
of Stroke and Embolism Trial in Atrial Fibrillation)
trial (12); and the ENGAGE AF–TIMI 48 study,
comparing edoxaban, a direct factor Xa inhibitor,
with warfarin (13).
DATA EXTRACTION AND QUALITY ASSESSMENT. Two
reviewers (G.S. and P.P.F.) independently selectedpotentially eligible trials. Discrepancies were
resolved by consensus. From each study, information
about the inclusion criteria, year of publication,
number of patients in treatment and control arms,
duration of follow-up, age, sex, cardiovascular (CV)
risk factors, prior myocardial infarction or coronary
artery disease, CHADS2 score, New York Heart Asso-
ciation (NYHA) functional class and baseline medi-
cations were abstracted by one author (G.S.) and
checked by another author (P.P.F.). Pre-speciﬁed
outcomes for the current analysis were the compos-
ite of stroke and systemic embolism (SSE), major
bleeding, intracranial bleeding, any bleeding, CV
mortality, and all-cause death. These data were
abstracted for subgroups of patients with and without
HF and randomized to NOACs or warfarin and were
available in published articles for apixaban (10),
dabigatran (11), and rivaroxaban (12), whereas they
were obtained directly from authors for edoxaban, as
the analyses of patients stratiﬁed by HF in ENGAGE
AF-TIMI 48 were still not published at the time of the
current meta-analysis. Patients were reported to be
affected or not by HF according to the different def-
initions used by the trials in which they were enrolled
(Table 1).
In 2 of 4 trials, 2 different dosages of NOACs
(dabigatran, 110 and 150 mg twice daily, in RE-LY; and
edoxaban, 30 or 60 mg once daily, in ENGAGE
AF-TIMI 48) were compared to those of warfarin
(11,13). In order not to merge the effects of different
doses, we performed a meta-analysis including the
higher dose arms of the RE-LY (11) and ENGAGE
AF-TIMI 48 (13) studies together with the single-
dosage arms of the ARISTOTLE (apixaban, 5 mg
twice daily) (10) and ROCKET AF (rivaroxaban, 20 mg
once daily) (12) trials.
Some outcome data were not available for the
secondary analyses: all-cause and CV mortality were
not reported in the ARISTOTLE and RE-LY HF sub-
groups (10,11), respectively. In the ROCKET AF HF
substudy, major bleeding was not reported, and
major or nonmajor clinically relevant bleeding was
used instead of any bleeding (12).
Methodological quality of trials was assessed by the
Detsky method, scoring the following items: method
of randomization: 1 point; adequate description of
method of randomization: 2 points; blindness: 2
points; adequate description of outcome: 1 point, and
of outcome assessment: 2 points; inclusion/exclusion
criteria: 2 points; number of patients excluded and
reasons: 2 points; description of therapy in treatment
and control groups: 4 points; and appropriateness of
statistical analysis: up to 5 points (16).
TABLE 1 Baseline Characteristics of Trials Included in the Analysis
ARISTOTLE ENGAGE AF RE-LY ROCKET AF TOTAL HF vs. No HF
HF No HF HF No HF HF No HF HF No HF HF No HF p Value
Year 2013 2015 2013 2013
Treatment Apixaban
5 mg twice daily
Edoxaban
60 mg once daily
Dabigatran
150 mg twice daily
Rivaroxaban
20 mg once daily
FUP, yrs 1.5 2.8 2.0 1.94 NA NA
Patients, % 5,943 8,728 8,145 5,926 3,263 8,835 9,033 5,138 26,384 28,627 NA
Females, % 33 35 38 38 34 39 39 40 36 38 <0.01
Age, yrs 69 71 70 75 68 73 72 74 70 73 0.03
CHADS2 2.46 1.88 3.00 2.60 2.65 2.00 3.70 3.15 2.95 2.41 0.22
Hypertension, % 83 90 94 93 75 80 93 86 86 87 <0.01
Diabetes, % 26 25 31 44 27 22 42 35 31 31 1.00
Prior MI/CAD, % 22 11 15 8 32 26 22 10 23 14 <0.01
NYHA functional
classes I-II, %
57 NA 78 NA NA NA 69 NA 68 NA NA
NYHA functional
classes III-IV, %
23 NA 22 NA NA NA 31 NA 25 NA NA
Aspirin, % 33 30 31 29 NA NA 31 25 32 28 <0.01
Detsky quality score 100% 100% 95% 100% 100% NA
Deﬁnition of HF Symptomatic
congestive HF
within 3 months
with reduced or
preserved
ejection fraction
Current presence
or history of HF
class C or D
according to the
AHA/ACC
deﬁnition*
Presence of NYHA
class II or higher
HF symptoms
within 6 months
in patients with
history of
previous
admission for HF
Left ventricular
ejection <40%
NA NA NA
*ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice
Guidelines. Circulation 2005;112;154–235.
ARISTOTLE ¼ Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; CAD ¼ coronary artery disease; ENGAGE-AF ¼ Effective Anticoagulation with Factor Xa Next
Generation in Atrial Fibrillation; FUP ¼ follow-up; HF ¼ heart failure; MI ¼ myocardial infarction; NA ¼ not available; NYHA ¼ New York Heart Association; RE-LY ¼ Randomized Evaluation of Long-Term
Anticoagulation Therapy; ROCKET AF ¼ Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation.
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873STATISTICAL ANALYSIS. Relative risks (RR) of the
outcomes in HF versus no-HF patients and of effects
of randomized treatments were calculated using the
metan routine (version 12.0 software, StataCorp LLC,
College Station, Texas) to account for the probability
of events occurring in the treatment group versus the
control group (17). RR and 95% conﬁdence interval
(CI) for each outcome were separately calculated for
each trial, with grouped data, using the intention-to-
treat principle (18). Pooled RRs were logarithmically
transformed and weighted for the inverse of variance.
Overall estimates of effect were calculated with a
ﬁxed-effects model or with a random effects model
when heterogeneity could not be explained. The
assumption of homogeneity between the treatment
effects in different trials was tested using Q statistic
and further quantiﬁed by I2 statistic. A signiﬁcant
heterogeneity was deﬁned by a p value of <0.05 at Q
statistic; i2 values ranging from 0% to 40% indicated
unimportant heterogeneity, 30% to 60% represented
moderate heterogeneity, 50% to 90% indicated sub-
stantial heterogeneity, and 75% to 100% represented
considerable heterogeneity (19). The signiﬁcancelevel for all outcome and heterogeneity analyses was
set at a p value #0.05.
SENSITIVITY ANALYSIS. To explore the inﬂuence of
potential effect modiﬁers on outcomes, weighted
randomeffectsmetaregression analysiswas performed
with the metareg command (version 12.0, Statacorp) to
test demographic characteristics of the study popula-
tion, duration of follow-up, CV risk factors, New York
Heart Association (NYHA) functional class, CHADS2
score, and concomitant medications (20). For all met-
aregression analyses, the weight used for each trial
was the inverse of the sum of the within-trial variance
and the residual between trial variance. Additionally,
the residual maximum likelihood methods were used
to explain residual heterogeneity not explained by
potential effect modiﬁers, including an additive
between-study variance component Tau2 (21).
Because the main analysis was performed by
pooling the trials with a single-dose arm (ARISTOTLE
and ROCKET AF) together with the higher dose arm of
the trials assessing 2 different doses of the same drug
(RE-LY and ENGAGE AF-TIMI 48), further analysis
FIGURE 1 Outcome Analysis in HF Versus No HF Subgroup
Risk ratios (RRs) for risk of stroke/embolism; major, total, and intracranial bleeding; and all-cause and cardiovascular death in patients with
versus those without heart failure (HF). Solid squares represent RRs in trials and have a size proportional to the number of events. The 95%
conﬁdence intervals (CIs) for individual trials are denoted by lines and those for the pooled RRs by diamonds. Event rates are reported as
events per patient-years. ARISTOTLE ¼ Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; CV ¼ car-
diovascular; ENGAGE-AF ¼ Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation; ER ¼ event rate; RE-LY ¼ Ran-
domized Evaluation of Long Term Anticoagulation Therapy; ROCKET-AF ¼ Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared
with Vitamin K Antagonism for Prevention of Stroke and Embolism Trail in Atrial Fibrillation.
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lower dose arms.
RESULTS
CHARACTERISTICS OF INCLUDED TRIALS. The 4
trials included in analyses of 55,011 subjects, 26,384
with HF, of whom 13,251 were treated with NOACs
and 13,133 with warfarin, and 28,627 without HF, of
whom 14,267 were treated with NOACs and 14,360
with warfarin (Figure 1). The median follow-up rangedfrom 1.5 to 2.8 years across the 4 trials. Characteristics
of patients with and without HF are reported in
Table 1. Patients with HF on average were younger
and less likely to be female and hypertensive but had
higher rates of diabetes and prior myocardial infarc-
tion or coronary artery disease.
METHODOLOGICAL QUALITY. The median Detsky
score was 100%, meaning that the quality of the trials
included in the meta-analysis was very high. All trials
satisﬁed all Detsky method items, except for RE-LY,
which was not double-blinded.
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total of 1.74 SSEs per 100 patient-years were reported
in HF patients compared with 1.67 in subjects without
HF; thus, the rates of SSE in patients with HF were
comparable to those in patients without HF (p ¼ 0.68)
(Figure 1). Similarly, 2.70 major bleedings per 100
patient-years occurred in HF patients and 3.02 in
subjects without HF, with no differences between the
subgroups (p ¼ 0.21).
Both the rates of intracranial bleeding (0.45 vs.
0.60 per 100 patient-years; p < 0.01) and any bleeding
(11.80 versus 15.62 per 100 patient-years; p < 0.01)
were signiﬁcantly lower in patients with HF than in
patients without HF. Rates of CV death (3.62 vs. 1.84
per 100 patient-years; p < 0.01) and all-cause death
(5.21 vs. 3.20 per 100 patient-years; p < 0.01) were
approximately 2-fold signiﬁcantly higher in HF
patients than in patients without HF.
TREATMENT ANALYSIS: EFFECTS OF NOACs IN HF
VERSUS NO HF SUBGROUPS. No differences in
treatment effect were detected between HF and
no-HF patients for SSE (p ¼ 0.23), major bleeding
(p ¼ 0.09), intracranial bleeding (p ¼ 0.32), any
bleeding (p ¼ 0.99), CV death (p ¼ 0.11), and all-cause
mortality (p ¼ 0.13) (Figure 2).
Effects of NOACs in HF pat ients . In patients with
HF, NOACs signiﬁcantly reduced the rate of SSE by
14.4% (p ¼ 0.01), major bleeding by 23.2% (p < 0.01),
intracranial bleeding by 57.3% (p < 0.01), and any
bleeding by 11.6% (p ¼ 0.02) compared with warfarin.
CV and all-cause death rates were not signiﬁcantly
different between NOAC- and warfarin-treated pa-
tients (p ¼ 0.11 and p ¼ 0.08, respectively) (Figures 2
and 3).
Effects of NOACs in pat ients without HF. NOACs
signiﬁcantly reduced the rate of SSE by 23.1%
(p < 0.01), major bleeding by 12.2% (p ¼ 0.01), and
intracranial bleeding by 49.0% (p < 0.01) compared
with warfarin. Rates of any bleeding were numeri-
cally lower with NOACs, but this did not meet statis-
tical signiﬁcance (p ¼ 0.054). NOACs signiﬁcantly
reduced both CV and all-cause death by 19.2%
(p ¼ 0.02) and 14.7% (p ¼ 0.04), respectively,
compared with warfarin (Figures 2 and 4).
Sens i t i v i ty ana lys i s . In ROCKET AF (12), major or
nonmajor clinical relevant bleeding was used instead
of any bleeding, as the latter was not available. For
this reason, we also excluded data from ROCKET AF
in a sensitivity analyses of the outcome of any
bleeding, and results were conﬁrmed in HF versus no-
HF analysis and within the HF subgroup. Within the
no-HF subgroup, after the removal of data from
ROCKET AF, NOACs signiﬁcantly reduced the risk ofany bleeding by 14.1% (RR: 0.86; 95% conﬁdence in-
terval [CI]: 0.77 to 0.96; comparison p ¼ 0.01; het-
erogeneity p < 0.01; i2 ¼ 88.3%).
In a metaregression analysis, no relevant effect
modiﬁers were identiﬁed that inﬂuenced the ﬁndings
of the meta-analysis (Online Table 1).
When lower dose arms of RE-LY and ENGAGE AF-
TIMI 48 trials were also included in the analyses
assessing the effects of NOACs on outcomes in HF
population (3,979 patients in edoxaban, 30 mg once
daily, arm of ENGAGE AF-TIMI 48 trial and 1,641
patients in dabigatran, 110 mg twice daily, arm of
RE-LY trial), NOACs signiﬁcantly reduced the risk of
major bleeding by 27.3% (RR: 0.73; 95% CI: 0.62
to 0.85]; comparison p < 0.01; heterogeneity p ¼
0.04; i2 ¼ 61.1%), total bleeding by 12.8% (RR: 0.87;
95% CI: 0.80 to 0.95; comparison p < 0.01; hetero-
geneity p < 0.01; i2 ¼ 78.3%), and intracranial
bleeding by 58.1% (RR: 0.42; 95% CI: 0.32 to 0.54;
comparison p < 0.01; heterogeneity p ¼ 0.257; i2 ¼
24.7%), without any effect on risk of SSE (RR: 0.94;
95% CI: 0.85 to 1.04; p comparison ¼ 0.241;
p heterogeneity ¼ 0.120; i2 ¼ 42.8%) and CV death
(RR: 0.94; 95% CI: 0.86 to 1.02; p comparison ¼ 0.123;
p heterogeneity ¼ 0.824; i2 ¼ 0.0% [data for edox-
aban, 30 mg once daily, were missing]). Data for all-
cause mortality in RE-LY and for edoxaban, 30 mg
once daily, were not available; therefore, this
outcome analysis could not be performed.
DISCUSSION
The ﬁndings of the present study indicate that
NOACs, compared with warfarin, signiﬁcantly reduce
the risk of SSE as well as the risk of major, intracra-
nial, and any bleeding in AF patients regardless of the
presence or absence of HF.
THROMBOEMBOLIC AND BLEEDING RISK IN PATIENTS
WITH AF AND HF. Current guidelines include HF
among the factors to be summed in the CHADS2 and
CHA2DS2-VASc risk scores (7), even though the evi-
dence that HF is associated with a higher thrombo-
embolic risk in patients with AF is reported in some
studies (3,4) but not in others (6,22,23). In fact, this
apparent discrepancy needs to be interpreted with
caution, taking into account the different enrollment
criteria adopted in the studies. In ARISTOTLE and
ROCKET AF, no differences in cardioembolic or
bleeding risk were observed between patients with
and without HF, although a higher mortality was
reported (10,12). In addition, in both of those trials
(10,12), no interaction was observed between ejection
fraction and SSE risk. However, patients enrolled in
FIGURE 2 Effects of NOAC in HF Versus No HF Subgroups
Risk Ratios (RRs) for risk of stroke/embolism; major, total, and intracranial bleeding; and all-cause and cardiovascular death in patients with and
without HF receiving novel oral anticoagulants versus warfarin. Solid squares represent RRs in trials and have a size proportional to the number
of events. The 95% CIs for individual trials are denoted by lines and those for the pooled RRs by diamonds. Event rates are reported as events
per patient-years. NOAC ¼ novel oral anticoagulant; other abbreviations as in Figure 1.
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stroke risk than patients in the other NOAC trials,
which might have diluted the prognostic impact of HF
(12). In the RE-LY trial, although the rate of SSE was
numerically higher in patients with HF than in those
without HF, after multivariate adjustment for base-
line characteristics, the risk of SSE was similar among
patients with and without HF, whereas in the same
analysis, HF was an independent risk factor for CV
death (11). In contrast to other NOAC phase III trials,
in ENGAGE AF-TIMI 48, signiﬁcantly higher SSE and
bleeding risks were observed in patients with HF,
after adjustment for other confounders (13). In our
analysis summarizing all the data from the 4 major
NOAC clinical trials, we found no differences in the
risk of either thromboembolic or major bleeding
events between patients with versus those without a
history of HF, but an increased mortality was present
in patients with HF.
It is important to recognize that HF is associated
with an increased likelihood of a suboptimal TTR in
AF patients treated with vitamin K antagonists
(8,9). Because inadequate control of the level ofanticoagulation increases the risk of thromboem-
bolic events, bleeding, and death, this might by it-
self contribute to increased risk in HF patients with
AF (9,13). In fact, a recent meta-analysis of all 4
major NOAC versus warfarin trials reported a
greater reduction in bleeding risk with NOACs in
patients enrolled at centers with a median
TTR <66% (14). In RE-LY, patients with HF,
compared with those without HF, showed a signif-
icantly lower rate of any bleeding, whereas no
signiﬁcantly reduced rate of intracranial bleeding in
patients with HF was observed in RE-LY, ARIS-
TOTLE, and ROCKET AF (10–12). In our analysis, the
rates of intracranial and of any bleeding were
signiﬁcantly lower in patients with HF than in pa-
tients without. This counterintuitive ﬁnding might
be explained in part by the enrollment criteria of
NOAC clinical trials, in which patients with HF,
compared with those without HF, were younger,
had a lower prevalence of hypertension, and,
consequently, had lower blood pressure values that
might explain in particular the reduced rates of
intracranial bleeding in these patients.
FIGURE 3 Effects of NOACs in HF Subgroup
Risk Ratios (RRs) for risk of stroke/embolism; major, total, and intracranial bleeding; and all-cause and cardiovascular death in patients with HF
receiving novel oral anticoagulants versus warfarin. Solid squares represent RRs in trials and have a size proportional to the number of events.
The 95% CIs for individual trials are denoted by lines and those for the pooled RRs by diamonds. Event rates are reported as events per patient-
years. Abbreviations as in Figures 1 and 2.
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877Finally, the absence of differences in the risk of
either thromboembolic or bleeding events shown in
our meta-analysis between patients with and those
without a history of HF does not deny the unfavor-
able impact of HF and could be explained by the
enrollment criteria used in the 4 NOAC trials. In fact,
to be enrolled in these trials, patients needed to
have AF plus only 1 additional risk factor, including
HF. This resulted in a selection bias among patients
without HF, as other major risk factors for SSE were
needed for participation in the trials, which might
have obscured the impact of HF on SSE and bleeding
risk. In addition, all patients in these trials received
anticoagulation therapy, whether they had HF or
not, and that might have attenuated any differencein thromboembolic and bleeding related to HF
status.
EFFICACY AND SAFETY OF NOACs IN HF VERSUS
NO-HF PATIENTS. This meta-analysis of HF patients
enrolled in the 4 major trials on NOACs allowed us to
investigate the overall effects of these drugs on major
efﬁcacy and safety end points.
In these 4 trials, NOACs achieved efﬁcacy and
safety outcomes that were at least as good as warfarin
in patients with HF.
In the main ARISTOTLE trial, apixaban signiﬁ-
cantly reduced the risk of SSE compared with
warfarin, and the subgroup analysis comparing pa-
tients with HF with reduced ejection fraction to
FIGURE 4 Effects of NOACs in No-HF Subgroup
Risk ratios (RRs) of risk of stroke/embolism; major, total, and intracranial bleeding; and all-cause and cardiovascular death in patients without
HF receiving novel oral anticoagulants versus warfarin. Solid squares represent RRs in trials and have a size proportional to the number of
events. The 95% CIs for individual trials are denoted by lines and those for the pooled RRs by diamonds. Event rates are reported as events per
patient-years. Abbreviations as in Figures 1 and 2.
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878patients without HF demonstrated no signiﬁcant
interaction between treatments and subgroups (10).
Risks of intracranial, major, and total bleeding were
signiﬁcantly reduced by apixaban compared with
warfarin in the main trial and to a similar degree in
subgroups stratiﬁed by HF, with no evidence of sub-
group by treatment interaction for these safety end-
points (10).
In RE-LY, no differences in treatment efﬁcacy were
reported between HF and no-HF subgroups (11). In
both the patients with and those without HF, intra-
cranial and any bleeding were signiﬁcantly reduced
by dabigatran, 150 mg twice daily, whereas no dif-
ferences were observed between dabigatran and
warfarin for major bleeding (11).In ROCKET AF, rivaroxaban compared with
warfarin did not signiﬁcantly reduce the risks of SSE,
bleeding, CV death, or overall mortality in patients
with or in patients without HF (12).
In ENGAGE AF-TIMI 48, edoxaban, 60 mg, was
similar to warfarin for the prevention of thromboem-
bolism, regardless of the presence or absence of prior
HF. In addition, edoxaban signiﬁcantly reduced CV
death and CV hospitalization even in patients with
severe HF. Regardless of HF severity, edoxaban
signiﬁcantly reduced the risk of major bleeding
and intracranial hemorrhage compared with
warfarin (13).
Our analysis shows that NOACs, compared with
warfarin, signiﬁcantly reduced the risks of SSE, major
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: AF patients with
HF enrolled in NOAC clinical trials have reduced rates of any and
intracranial bleeding, but increased rates of all-cause and CV
death. NOACs, compared with warfarin, signiﬁcantly reduce SSE
and major, intracranial, and any bleeding in AF patients regard-
less of the presence or absence of HF.
TRANSLATIONAL OUTLOOK: NOACs represent a valuable
and preferable alternative to warfarin in HF clinical setting.
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879and intracranial bleeding, and any bleeding in pa-
tients with HF, with no signiﬁcant interactions with
patients without HF. Furthermore, when the lower
dosage arms of RE-LY (11) and ENGAGE AF-TIMI 48
(13) were also included in the analysis, NOACs were
still shown not to be inferior to warfarin in reducing
the risk of SSE but superior in reducing the risk of
bleeding in AF patients with HF. Thus, NOACs
represent a valuable and preferable alternative to
warfarin in this clinical setting. The current meta-
analysis conﬁrms and expands the previous study
performed by Xiong et al. (15). The inclusion of data
from ENGAGE AF-TIMI 48 and the evaluation of other
outcome data not reported in the previous meta-
analysis complement the previous analysis and
further strengthen the efﬁcacy and safety of NOACS
in HF patients.
STUDY LIMITATIONS. The current meta-analysis has
some limitations to acknowledge. First, the studies
included in the analysis were not prospectively
designed to assess the efﬁcacy and safety of NOACs in
patients with HF versus without HF. Consequently,
the deﬁnitions of HF varied across trials, and this
could have led to consider patients with similar
characteristics as affected by HF in some trials but not
in others, with the possibility of introducing a bias in
the analysis. Additionally, our analyses were based
on aggregate trial-level data and not on patient-level
data. However, we performed meta-regression to
assess for potential confounding by differences in
baseline characteristics in patients with versus
without HF, and the results were similar. Because we
did not have patient-level data, we could not perform
subgroup analyses to assess the impact of treatment
in relation to relevant clinical characteristics,
including TTR, level of left ventricular dysfunction,
renal impairment, or other comorbid conditions
commonly observed in HF patients. It is also impor-
tant to acknowledge that our results cannot begeneralized to the overall AF population with HF but
may be applied only to patients showing similar
characteristics to those enrolled in NOACs random-
ized clinical trials. Finally, the J-ROCKET study (24),
even if it was a phase III trial randomizing AF patients
to NOAC (rivaroxaban) versus warfarin, was not
included in the analysis because it would have been
the only trial with a smaller sample size and enrolling
patients in just 1 country, leading to the possibility of
including a bias and generating heterogeneity in our
analysis.
CONCLUSIONS
In HF patients NOACs signiﬁcantly reduced the
risks of SSE and bleeding events, including major
bleeding and intracranial hemorrhage, compared
with warfarin. No interaction in the efﬁcacy or safety
proﬁle of NOACs compared with warfarin was present
in patients with versus those without HF.
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